Alitretinoin: In severe chronic hand eczema

Drugs

Volumn 69, Issue 12, 2009, Pages 1625-1634

  Garnock Jones, Karly P ^a,b   Perry, Caroline M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CORTICOSTEROID; CYCLOSPORIN; ETHINYLESTRADIOL PLUS NORGESTIMATE; KETOCONAZOLE; PLACEBO; RETINOIC ACID RECEPTOR; RETINOID DERIVATIVE; RETINOID X RECEPTOR; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA; SIMVASTATIN; TETRACYCLINE; TOCTINO; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR MALFORMATION; CENTRAL NERVOUS SYSTEM MALFORMATION; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CLEFT PALATE; CLINICAL TRIAL; COLOR BLINDNESS; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR MALFORMATION; ECZEMA; ENTERITIS; ERYTHEMA; EYE DISEASE; EYE MALFORMATION; FACE MALFORMATION; FETUS MALFORMATION; GASTROINTESTINAL SYMPTOM; HAND ECZEMA; HEADACHE; HEPATOBILIARY DISEASE; HOT FLUSH; HUMAN; IMMUNOMODULATION; INTRACRANIAL HYPERTENSION; LABORATORY TEST; LIP DISEASE; MUSCULOSKELETAL DISEASE; NIGHT VISION; PARATHYROID DISEASE; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SPONTANEOUS ABORTION; THYMUS DISEASE; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CHILD; CHRONIC DISEASE; ECZEMA; FEMALE; HAND; HUMANS; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOID X RECEPTORS; SKIN; TRETINOIN;

EID: 68949149237     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202200-000000000-00000     Document Type: Review

References (29)

1. Diepgen TL, Agner T, Aberer W, et al. Management of chronic hand eczema. Contact Dermatitis 2007 Oct; 57 (4): 203-10
2. Coenraads PJ. Hand eczema is common and multifactorial. J Invest Dermatol 2007 Jul; 127 (7): 1568-70
3. Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis 2008 Jul; 59 (1): 43-7
4. Hieke K, Scheidt R, Weisshaar E, et al. Societal costs of severe chronic hand eczema in Germany [abstract no. PSS29]. Value Health 2008; 11 (6): A618. Plus poster presented at the 11th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research; 2008 Nov 8-11; Athens
5. Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther 2004; 17 (3): 240-50
6. Schoepe S, Schacke H, May E, et al. Glucocorticoid therapyinduced skin atrophy. ExpDermatol 2006 Jun; 15 (6): 406-20
7. Basilea Pharmaceutica. Toctino® (alitretinoin): UK summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/ printfriendlydocument.aspx?documentid=21177&companyid=2359 [Accessed 2009 Feb 19]
8. Cheer SM, Foster RH. Alitretinoin. Am J Clin Dermatol 2000 Sep 31; 1 (5): 307-14
9. Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebocontrolled, multicentre trial. Br J Dermatol 2008 Apr; 158 (4): 808-17
10. Bollag W, Ott F. Successful treatment of chronic hand eczema with oral 9-cis-retinoic acid. Dermatology 1999; 199 (4): 308-12
11. Gottardis MM, Lamph WW, Shalinsky DR, et al. The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat 1996; 38 (1): 85-96
12. Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992 Jan 24; 68 (2): 397-406
13. Willy PJ, Umesono K, Ong ES, et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995 May 1; 9 (9): 1033-45
14. Zhang XK, Lehmann J, Hoffmann B, et al. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 1992 Aug 13; 358 (6387): 587-91
15. Xu J, Drew PD. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol 2006 Feb; 171 (1-2): 135-44
16. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006 Dec; 58 (4): 760-72
17. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 2006 Dec; 58 (4): 712-25
18. Geiger JM, Hommel L, Harms M, et al. Oral 13-cis retinoic acid is superior to 9-cis retinoic acid in sebosuppression in human beings. J Am Acad Dermatol 1996 Mar; 34 (3): 513-5
19. Coenraads P, van der Wetering J, Roos B, et al. Pharmacokinetics, efficacy and safety of alitretinoin (9-cis retinoic acid) in moderate or severe refractory chronic hand eczema [poster no. FP1620]. 17th Annual Congress of the European Academy of Dermatology and Venereology; 2008 Sep 17-20; Paris
20. Schmitt-Hoffman A, Roos B, Van Lier JJ, et al. Alitretinoin (9-cis retinoic acid): mass-balance excretion study of oral alitretinoin in healthy volunteers [poster no. P289]. 16th Annual Congress of the European Academy of Dermatology and Venereology; 2007 May 16-20; Vienna
21. Maares J, Roos B, Kovacs P, et al. Influence of food on the pharmacokinetics of oral alitretinoin [poster no. PB.50]. 9th Congress of the European Society of Contact Dermatitis; 2008 May 28-31; Estoril (Portugal)
22. Schmitt-Hoffman A, Meyer I, Weidekamm E, et al. Alitretinoin (9-cis retinoic acid): low levels in seminal fluid after repeated oral dosing [abstract no. P290]. 16th Annual Congress of the European Academy of Dermatology and Venereology; 2007 May 16-20; Vienna
23. Schmitt-Hoffmann A, Roos B, Baumgaertner E, et al. Alitretinoin (9-cis retinoic acid): pharmacokinetic interactions between alitretinoin, ketoconazole, simvastatin and cyclosporine A [poster no. P286]. 16th Annual Congress of the European Academy of Dermatology and Venereology; 2007 May 16-20; Vienna
24. Maares J, Roos B, Weidekamm E, et al. Influence of alitretinoin on pharmacokinetics of an oral contraceptive [poster no. PB.51]. 9th Congress of the European Society of Contact Dermatitis; 2008 May 28-31; Estoril (Portugal)
25. Ruzicka T, Larsen FG, Galewicz D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004; 140 (12): 1453-9
26. Coenraads P, Ruzicka T, Lynde C, et al. Alitretinoin re-induces response in relapsed CHE patients [poster no. PB.49]. 9th Congress of the European Society of Contact Dermatitis; 2008 May 28-31; Estoril (Portugal)
27. Ruzicka T. The next step in severe chronic hand eczema? Alitretinoin phase III results [oral presentation]. 16th Annual Congress of the European Academy of Dermatology and Venereology; 2007 May 16-20; Vienna
28. Elsner P. Dose-dependent time to response with oral alitretinoin in severe CHE [oral presentation]. 8th Congress of the European Society of ContactDermatitis; 2006 Sep 13-16; Berlin
29. Ruzicka T. Alitretinoin induces complete response and can re-induce response in patients with severe CHE [oral presentation]. 17th Annual Congress of the European Academy of Dermatology and Venereology; 2008 Sep 17-20; Paris